Clinical trials
Alzheimer's Disease Dementia clinical trials
Below are recruiting alzheimer's disease dementia clinical trials, each written for real people, not researchers. We’re tracking 465 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07786116Recruiting
Gut bacteria in Parkinson's disease and related conditions
This study looks at how certain gut bacteria (methanogens) are involved in the progression of Parkinson's disease and related conditions. It aims to understand the connection between gut health and brain health, which may lead to better treatments.
Cambridge, CB2Ages 55 years+ - NCT07158905RecruitingPhase 1
Tau vaccine study for early Alzheimer's prevention
This study tests a vaccine that targets tau protein, which is linked to Alzheimer's disease. It is for older adults who have no memory problems yet but have biological signs of early Alzheimer's, to see if the vaccine can prevent or slow down the disease.
Boca Raton, FloridaAges 65–80 - NCT07213700Recruiting
Long-term study on Alzheimer's disease
This study follows people who are either being evaluated for Alzheimer's disease or have already been diagnosed. Researchers want to track their health over many years to better understand the disease and how treatments affect it.
GrazAges Any age - NCT07741071RecruitingPhase 2
Vitamin B3 supplement for early Alzheimer's disease
This study tests whether a daily supplement (nicotinamide riboside, a form of vitamin B3) can slow the progression of early Alzheimer's disease over two years. It is a randomized, double-blind trial, meaning half the participants will get the supplement and half will get a placebo (a pill with no active ingredient), and neither you nor the doctors will know which you are getting.
BergenAges 50–85 - NCT06416072Enrolling by invitation
Blood marker study for people not eligible for Alzheimer's prevention trials
This study looks at blood markers in people who were part of an early Alzheimer's prevention study but did not qualify for it because their amyloid levels were too low. It aims to understand brain changes and possibly find ways to detect Alzheimer's even earlier.
Birmingham, AlabamaAges 55–80 - NCT07768579Recruiting
Sequential treatment for Alzheimer's disease
This study tests a sequence of treatments to see if they can help people with Alzheimer's disease or mild cognitive impairment. It aims to slow down memory decline and improve daily function.
Beijing, Beijing MunicipalityAges 55–85 - NCT05617014Enrolling by invitation
ADNI4 study for early Alzheimer’s with brain imaging tests
This study enrolls people with no memory impairment, mild memory problems, or mild Alzheimer’s dementia to test how brain scans and cognitive tests relate to Alzheimer’s disease. It may help by contributing to better early diagnosis and by letting you see whether you fit into the study’s imaging and blood-test pathway.
Birmingham, AlabamaAges 55–90 - NCT07757178Recruiting
Dementia lived experiences study
This study explores the personal stories and experiences of people with dementia, their families, and caregivers to help improve care and support. Participation involves sharing your experiences in interviews or other tasks.
Nottingham, EnglandAges 18–99 - NCT07688213RecruitingPhase 2
Study of an investigational drug for early Alzheimer's disease
This trial tests an investigational injection for people in the early stages of Alzheimer's. It aims to see if the drug can safely slow down memory loss and brain changes.
The Villages, FloridaAges 55–85 - NCT06936514Enrolling by invitation
Lymphatic surgery for Alzheimer's: a clinical study
This trial tests a surgery that targets the lymphatic system in the neck to help people with moderate-to-severe Alzheimer's disease. The goal is to see if it can improve cognitive function.
TianjinAges 50–80 - NCT06803823RecruitingPhase 2
Testing a new drug for agitation in Alzheimer's
This study tests an experimental drug, ONO-2020, to see if it can help reduce agitation in people with Alzheimer's disease. Agitation can include restlessness, pacing, or verbal outbursts, and this trial aims to find a new treatment option.
AichiAges 55–90 - NCT07284472RecruitingPhase 2/Phase 3
Testing drugs for agitation in Alzheimer's disease
This trial tests two new drugs (EXV-802 and EXV-801) to see if they can safely reduce moderate to severe agitation in people with Alzheimer's dementia. If you or a loved one has Alzheimer's and has been experiencing significant agitation for at least two weeks, this study may be an option.
Murrieta, CaliforniaAges 55–90 - NCT07724132RecruitingPhase 3
Treatments for sustained response in Alzheimer's disease
This study tests whether a treatment (atomoxetine or metformin) can help people with Alzheimer's disease maintain an improved state for at least 18 months. It may help you or a loved one stabilize symptoms and slow disease progression.
CambridgeAges 55 years+ - NCT06847321RecruitingPhase 2
Testing LHP588 for Alzheimer's linked to a mouth bacteria
This trial tests a new medication, LHP588, for people with Alzheimer's who also have a common mouth bacteria called P. gingivalis. The goal is to see if targeting this bacteria can help slow down memory loss.
Phoenix, ArizonaAges 55–80 - NCT05552157RecruitingPhase 2/Phase 3
Study of treatments for early onset Alzheimer's caused by genetic mutations
This trial tests potential treatments for people who are at risk for or have early onset Alzheimer's disease due to a specific genetic mutation. It aims to find treatments that could slow or prevent symptoms.
Birmingham, AlabamaAges 18 years+ - NCT06647498RecruitingPhase 2/Phase 3
Study of a treatment for early-onset Alzheimer's caused by a gene change
This study tests a potential disease-modifying treatment for people who have a specific gene mutation that causes early-onset Alzheimer's disease. The goal is to see if the treatment can delay or prevent symptoms.
Birmingham, AlabamaAges 18 years+ - NCT07721701Recruiting
Digital Dementia Registry for Bavaria
This study follows people with mild cognitive impairment or dementia and their family caregivers over time. It aims to learn more about how these conditions progress and how to improve care, especially for those living in Bavaria.
AschaffenburgAges Any age - NCT07717567Recruiting
Blood tests to diagnose and predict Alzheimer's disease
This study is testing whether a simple blood test can help diagnose Alzheimer's disease and predict how the disease will progress. If you have memory or thinking problems that have been getting worse, you may be able to join.
Milan, MilanoAges 40 years+ - NCT02740634Recruiting
Brain imaging study for Alzheimer's disease
This study uses brain scans to understand Alzheimer's disease and related conditions that affect memory, language, or vision. It looks at how changes in the brain happen over time in people with these diagnoses.
Rochester, MinnesotaAges 21–80 - NCT03019757Recruiting
Testing ways to tell dementia causes apart
This study looks at how to distinguish Alzheimer’s disease, Lewy body dementia, and Parkinson’s disease when someone has memory and thinking problems. It may help doctors choose the most accurate diagnosis and treatment path for the right condition.
Columbus, OhioAges 18 years+ - NCT03174938Recruiting
BioFINDER 2 study for healthy aging and memory problems
This study uses brain scans and a spinal fluid test to better understand memory and thinking changes in different groups, from people with healthy thinking to early or established dementia. If you qualify, it may help researchers learn what’s driving these conditions and how they progress.
ÄngelholmAges 20–100 - NCT03233646Recruiting
Retina scans in memory and nerve disorders
This study uses pictures of the back of your eye (retinal imaging) to look for differences in people with neurodegenerative diseases and compares them with people without these conditions. It may help researchers understand eye changes that could connect to brain or nerve health.
Durham, North CarolinaAges 18 years+ - NCT03402919Recruiting
Brain and memory study for people with thinking changes
This study looks at memory and thinking changes using questionnaires, memory testing, and brain scans. It may help researchers better understand neurodegeneration and dementia and how these problems show up over time.
Calgary, AlbertaAges 50–90 - NCT03621839Recruiting
Study of new spinal-fluid tests for Alzheimer’s disease
This study looks at new test markers found in spinal fluid to help with diagnosing Alzheimer’s disease. If you are already getting a spinal-fluid sample as part of your dementia workup, this trial may check it for additional information.
Nancy, Grand EstAges Any age
Hear when a new Alzheimer's Disease Dementia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer's disease dementia?
- Yes. Clin2 currently lists 465 recruiting alzheimer's disease dementia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer's disease dementia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer's disease dementia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.